Abstract
Growth factors of the bombesin/gastrin releasing peptide (BN/GRP) family play a critical role in proliferation and progression of malignancies. Inhibitors targeting GRP signalling have been developed and tested as anticancer compounds showing promising preclinical and early phase clinical results. In this review, we will discuss the molecular signaling, expression and the functional role of BN/GRP-GRPR in different cancer models and will focus on the available strategies to target BN/GRP-GRPR in cancer treatment as well as in tumour diagnosis and follow up.
Original language | English |
---|---|
Pages (from-to) | 508-514 |
Number of pages | 7 |
Journal | Current Drug Targets |
Volume | 17 |
Issue number | 5 |
Publication status | Published - Apr 1 2016 |
Keywords
- Cancer
- Clinical trial
- Drug targets
- Neuropeptide
- Signaling transduction
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
- Clinical Biochemistry
- Molecular Medicine